الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 169 |  |  |
| | | from | 169 | | |
Abstract
Androgenetic alopecia is a genetically disorder characterized by the gradual conversion of terminal hairs into vellus hairs, called miniaturized hairs. It is an extremely common disease that affects men and women.
Specifically, DP cells that are the main regulators of hair growth and are the only site of 5α-DHT action.
Male-pattern hair loss; Male note gradual recession of the frontal hair line early in the process. Men present with gradual thinning in the temporal areas, producing a reshaping of the anterior part of the hair line.
Minoxidil was the first drug to be approved in treatment of AGA, it’s a vasodilator medication known for its ability to slow or stop hair loss and promote hair regrowth. The exact mechanism of action of minoxidil is uncertain, but it has been suggested that it promotes hair growth by opening adenosine triphosphate-sensitive potassium channels and stimulating the synthesis VEGF in DP cells.
Topical minoxidil has been evaluated for response in different strengths from 1% to 15% in AGA. Result can be variable, and historical experience suggests that higher concentration of topical minoxidil as 10% may enhance efficacy.
The main aim of this study was to evaluate and compare topical minoxidil 10% versus topical minoxidil 5% in the treatment of MPHL as regards the efficacy, safety and side effects. This study included 51 patients with MPHL divided into 2 groups received topical minoxidil 5% 1ml twice daily for 6 months and the second group received topical minoxidil 10% 1ml twice daily for 6 months.
As regard the assessment of the response to treatment by the change in trichoscopic features in both groups, in the minoxidil 5% group and in the minoxidil 10% group showed that there was significant improvement in all trichoscopic features in all regions (frontal, vertex and temporal regions).
The current study revealed that there was significant difference between the studied groups as regard the percentage of improvement in Frontal Total hair count with superiority for 10% group. But the improvement in other parameters were comparable between the studied groups.
Comparison of treatment response in both groups revealed nearly the same efficacy of both concentrations of topical minoxidil 5% and 10% in MPHL, higher concentration more than 5% could decrease the compliance and the tolerance.
In conclusion, we found that using higher doses of topical minoxidil was associated with higher improvement in frontal total hair count and higher side effects.